Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming ...

Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenstrom macroglobulinemia ...

Michi has been an oncology nurse for more than 20 years and continues to make an impact in the field. Michi has expertise in ...

Discrepancies between patients' experiences and friends' lives can strain relationships, highlighting the need for ...

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 ...

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Dr. Neha Mehta-Shah shares how patients can better understand their subtype of rare lymphoma, as well as expands on the ...

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic ...